Elevated cellular PD1/PD-L1 expression confers acquired resistance to cisplatin in small cell lung cancer cells

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Yan, Fei ^a   Pang, Jiuxia ^a   Peng, Yong ^b   Molina, Julian R ^c   Yang, Ping ^c   Liu, Shujun ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SICHUAN UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA METHYLTRANSFERASE 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE KIT; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; PDCD1 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL EXPANSION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; SMALL CELL LUNG CANCER; UPREGULATION; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD274; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; UP-REGULATION;

EID: 84990951666     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162925     Document Type: Article

References (46)

1. Govindan R, Page N, Morgensztern D, ReadW, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. Epub 2006/09/30. doi: 10.1200/JCO.2005.04.4859 PMID: 17008692.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings. 2008; 83(5):584-94. doi: 10.4065/83.5.584 PMID: 18452692; PubMed Central PMCID: PMC2718421.
3. Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. Journal of thoracic disease. 2013; 5 Suppl 5:S565-78. doi: 10.3978/j.issn.2072-1439.2013.07.43 PMID: 24163749; PubMed Central PMCID: PMC3804877.
4. Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer-do we have more choice' British journal of cancer. 2010; 102(4):629-38. doi: 10.1038/sj.bjc. 6605527 PMID: 20104223; PubMed Central PMCID: PMC2837580.
5. PietanzaMC. Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(10):1027-9. doi: 10.1200/JCO.2015.65. 6462 PMID: 26884572.
6. Crivellari G, Monfardini S, Stragliotto S, MarinoD, Aversa SM. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. The oncologist. 2007; 12(1):79-89. doi: 10. 1634/theoncologist.12-1-79 PMID: 17227903.
7. Hagmann R, Hess V, Zippelius A, Rothschild SI. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO)-A Single Center Experience. Journal of Cancer. 2015; 6(11):1148-54. doi: 10.7150/jca. 13080 PMID: 26516363; PubMed Central PMCID: PMC4615351.
8. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007; 25 (15):2086-92. doi: 10.1200/JCO.2006.08.3998 PMID: 17513814.
9. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. doi: 10.1038/nrc2167 PMID: 17625587.
10. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008; 283(10):6572-83. doi: 10.1074/jbc. M707568200 PMID: 18162465.
11. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation throughROS generation. Apoptosis: an international journal on programmed cell death. 2007; 12(9):1733-42. doi: 10.1007/s10495-007-0082-8 PMID: 17505786.
12. Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. Journal of nucleic acids. 2010;2010. doi: 10.4061/2010/201367 PMID: 20811617; PubMed Central PMCID: PMC2929606.
13. Giaccone G, Splinter TA, DebruyneC, Kho GS, Lianes P, van Zandwijk N, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998; 16(6):2133-41. Epub 1998/06/17. PMID: 9626213.
14. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31(15):1869-83. doi: 10.1038/onc.2011.384 PMID: 21892204.
15. Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Molecular cancer therapeutics. 2004; 3(3):327-34. PMID: 15026553.
16. Tang CH, Parham C, Shocron E, McMahon G, Patel N. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol. 2011; 67(6):1389-400. doi: 10.1007/s00280-010-1435-5 PMID: 20809122; PubMed Central PMCID: PMC3102205.
17. Wu W, Wang HD, GuoW, Yang K, Zhao YP, Jiang YG, et al. Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. Journal of experimental& clinical cancer research: CR. 2010; 29:49. doi: 10.1186/1756-9966-29-49 PMID: 20470393; PubMed Central PMCID: PMC2877011.
18. He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific reports. 2015; 5:13110. doi: 10.1038/srep13110 PMID: 26279307; PubMed Central PMCID: PMC4538573.
19. Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer biology & medicine. 2015; 12(2):74-8. doi: 10.7497/j.issn.2095-3941.2015.0022 PMID: 26175922; PubMed Central PMCID: PMC4493379.
20. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8(8):793-800. doi: 10.1038/nm730 PMID: 12091876.
21. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current opinion in immunology. 2012; 24(2):207-12. doi: 10.1016/j.coi.2011.12.009 PMID: 22236695; PubMed Central PMCID: PMC3319479.
22. Kleffel S, Posch C, BarthelSR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015; 162(6):1242-56. doi: 10.1016/j.cell. 2015.08.052 PMID: 26359984; PubMed Central PMCID: PMC4700833.
23. Herbst RS, Soria JC, Kowanetz M, Fine GD, HamidO, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. doi: 10.1038/nature14011 PMID: 25428504.
24. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determinessensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. doi: 10.1126/science.aaa1348 PMID: 25765070.
25. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004; 10(15):5094-100. doi: 10.1158/1078-0432.CCR-04-0428 PMID: 15297412.
26. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical oncology. 2011; 28(3):682-8. doi: 10.1007/s12032-010-9515-2 PMID: 20373055.
27. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British journal of cancer. 2015; 112 (1):95-102. doi: 10.1038/bjc.2014.555 PMID: 25349974; PubMed Central PMCID: PMC4453606.
28. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. The Journal of experimental medicine. 2015; 212(2):139-48. doi: 10.1084/jem.20140559 PMID: 25601652; PubMed Central PMCID: PMC4322048.
29. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. doi: 10.1073/pnas.0810958105 PMID: 19088198; PubMed Central PMCID: PMC2634900.
30. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4):252-64. doi: 10.1038/nrc3239 PMID: 22437870.
31. Shen DW, Pouliot LM, Hall MD, GottesmanMM. Cisplatin resistance: a cellular self-defense mechanism resulting frommultiple epigenetic and genetic changes. Pharmacol Rev. 2012; 64(3):706-21. doi: 10.1124/pr.111.005637 PMID: 22659329; PubMed Central PMCID: PMC3400836.
32. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer letters. 2011; 308(2):134-43. doi: 10.1016/j.canlet.2011.03.014 PMID: 21669489.
33. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Molecular cancer therapeutics. 2005; 4(7):1096-104. doi: 10.1158/1535-7163.MCT-05-0081 PMID: 16020667.
34. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014; 46(4):364-70. doi: 10.1038/ng.2913 PMID: 24584072; PubMed Central PMCID: PMC4086945.
35. SharmaSV, Lee DY, Li B, QuinlanMP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. doi: 10.1016/j. cell.2010.02.027 PMID: 20371346; PubMed Central PMCID: PMC2851638.
36. Yan F, Shen N, Pang J, Molina JR, Yang P, Liu S. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells. J Biol Chem. 2015; 290(30):18480-94. doi: 10.1074/jbc. M114.633693 PMID: 26085088; PubMed Central PMCID: PMC4513109.
37. Yu W, Jin C, Lou X, Han X, Li L, He Y, et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PloS one. 2011; 6 (12):e29450. Epub 2012/01/05. doi: 10.1371/journal.pone.0029450 PMID: 22216282; PubMed Central PMCID: PMC3245283.
38. Zeller C, DaiW, Steele NL, Siddiq A,Walley AJ, Wilhelm-BenartziCS, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. Epub 2012/01/18. doi: 10.1038/onc.2011.611 PMID: 22249249.
39. O'Byrne KJ, BarrMP, Gray SG. The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers. 2011; 3(1):1426-53. Epub 2011/01/01. doi: 10.3390/cancers3011426 PMID: 24212667; PubMed Central PMCID: PMC3756421.
40. LiW, MeltonDW. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene. 2012; 31(19):2412-22. Epub 2011/10/15. doi: 10.1038/onc.2011.426 PMID: 21996734.
41. Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, et al. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. International journal of gynecological cancer: official journal of the InternationalGynecological Cancer Society. 2014; 24 (1):61-9. Epub 2013/12/24. doi: 10.1097/IGC.0000000000000014 PMID: 24362713.
42. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007; 67(13):6325-32. Epub 2007/07/10. doi: 10.1158/0008-5472.CAN-06-4261 PMID: 17616691.
43. Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother. 2013; 25(3):162-9. doi: 10.1179/1973947812Y. 0000000056 PMID: 23783141.
44. Yan F, Shen N, Pang J, Xie D, Deng B, Molina JR, et al. Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell death & disease. 2014; 5: e1413. Epub 2014/09/12. doi: 10.1038/cddis.2014.380 PMID: 25210796.
45. Gao XN, Yan F, Lin J, Gao L, Lu XL,Wei SC, et al. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015; 29(8):1730-40. doi: 10.1038/leu. 2015.56 PMID: 25727291.
46. Shen N, Yan F, Pang J, Wu LC, Al-Kali A, Litzow MR, et al. A nucleolin-DNMT1 regulatoryaxis in acute myeloid leukemogenesis. Oncotarget. 2014; 5(14):5494-509. Epub 2014/07/13. PMID: 25015109; PubMed Central PMCID: PMC4170608.